000			03992nam a2200493 i 4500
999			_c382749 _d382749
001			382749
003			ES-MaUEC
005			20230102122011.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			220325s2022 si | o |||| 0|eng d
020			_a9789811689574
024	7		_a10.1007/978-981-16-8957-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC756 _b2022 EB
245	0	0	_aMicrobiome in Inflammatory Lung Diseases _cedited by Gaurav Gupta, Brian G. Oliver, Kamal Dua, Alisha Singh, Ronan MacLoughlin
250			_aFirst edition 2022
264		1	_aSingapore _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XIV, 377 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aIntroduction to Lung Diseases -- Introduction to Microbiome -- Role of Microbiome in Inflammation -- The interplay of microbiome, inflammation, and immunity in inflammatory lung diseases -- Microbiome in Asthma -- Microbiome in Chronic Obstructive Pulmonary Disease -- Microbiome in Asthma-COPD Overlap syndrome (ACO) -- Microbiome in ARDS (Acute Respiratory Distress Syndrome) -- Role of brain-gut- microbiome axis in Depression co-morbid with COPD or Asthma -- Microbiome in Lung Cancer -- Microbiome in Pulmonary Tuberculosis -- Lung Microbiome: Friend or Foe of Mycobacterium tuberculosis -- Microbiome in Idiopathic Pulmonary Fibrosis. Microbiome in SARS-Cov2 (Covid-19) -- Status of the microbiome in SARS-Cov2 (Covid-19) -- Microbiome in Influenza-A Virus Infection -- Microbiome in Upper Respiratory Tract Infection (URTI) -- Challenges in understanding the lung microbiota -- Microbiome in Inflammatory Lung Diseases: Challenges and Future Prospects -- Microbiota targeted via nanotechnology for lung cancer therapy: Challenges and future perspectives.
520			_aThis book reviews the role of the lung microbiome in the development and progression of lung diseases. It deals with the role of microbiota dysbiosis in influencing host defense and immunity leading to resistance, colonization, and disease exacerbation. The book delineates the complex interaction between pathogen and lung residual microbiota during disease conditions. It further highlights the potential role of lung microbiota as the key modulator of lung carcinogenesis and immune response against cancer cells. Lastly, it reviews technological developments for unraveling the lung microbiome that profoundly impacts clinical diagnostics. This book is an essential resource for the scientists working in pulmonary diseases, pharmaceutical & clinical sciences, and pulmonary clinicians.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9168957 _aPulmones _xEnfermedades
650		7	_2embne _9405049 _aMicrobiología médica
700	1		_aGupta, Gaurav. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aOliver, Brian G. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aDua, Kamal. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aSingh, Alisha. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMacLoughlin, Ronan. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9789811689567
776	0	8	_iPrinted edition: _z9789811689581
776	0	8	_iPrinted edition: _z9789811689598
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-16-8957-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eb _zSI